In the rapidly evolving pharmaceutical landscape, innovative solutions are crucial for streamlining drug development and manufacturing processes. PharmaDEM Solutions Private Limited, an Indian start-up incubated at ASPIRE-TBI in University of Hyderabad (UoH), is at the forefront of this revolution, leveraging advanced simulation and modelling technologies to transform the pharma industry.
Founded in 2020 by Dr. Ravi Pyaraka, Dr. Ravi Shekhar, and Dr. Deepa G, PharmaDEM specializes in digital engineering, advanced simulation, and consulting services for the pharmaceutical sector. With a strong focus on technology integration, the company offers proprietary software products, including FormDEM for formulation modelling and SoluDEM for solubility prediction. These cutting-edge tools enable pharmaceutical companies to accelerate and optimize drug development, reducing trial-and-error and minimizing costs and time-to-market.
The Key Strengths of PharmaDEM include:
– Simulation Capabilities: PharmaDEM’s technology simulates both quantum and classical molecular interactions, optimizing reaction chemistry and solving complex manufacturing challenges.
– Consulting Services: The company provides expert consulting services for generic and innovative drug manufacturing, ensuring better control of production parameters and compliance with regulatory standards.
– Digitalization: PharmaDEM’s eLab Notebook digitalizes and records lab experiments, streamlining R&D processes and saving time and costs.
Milestones and Achievements of PharmaDEM
– Commercial Product Launch: PharmaDEM launched commercial products for formulations and APIs in 2023, marking a significant milestone in its journey.
– Process Simulation: The company successfully delivered process simulation for blend uniformity to a client with a large commercial-scale blender in Asia.
– Revenue Growth: PharmaDEM’s turnover doubled in 2024, with a cumulative value of approximately ₹2 crores per year and assets worth ₹1 crore.
– Patents and IPs: The company holds three patents and three intellectual properties, with one IP accomplished and two in progress.
The initial challenge for the PharmaDEM was bringing commercial products to the Pharma fraternity. The company surmounted this challenge with the funding enablement by ASPIRE under Startup India Seed Fund Scheme (SISFS). The revenue generated by the PharmaDEM after incubation at TBI was fifty lakhs for the financial year 2022- 2023, and one hundred and twenty-five lakhs for the financial year 2023- 2024. The funding enablement helped the company to bring commercial products to its clients.
As a forward-thinking start–up, the PharmaDEM put forth certain specific suggestions regarding the facility provided by ASPIRE under Startup India Seed Fund Scheme (SISFS), including raising the funding opportunities, increasing the funding grant to meet the current costs of organization, and relaxation on eligibility criteria too.
With its cutting-edge technology, expertise, and commitment to excellence, the company is poised to make a significant impact in the pharma sector. As a shining example of innovation and entrepreneurship, PharmaDEM’s success story serves as an inspiration for aspiring start-ups and entrepreneurs. For any further details please email: ravip@pharmadem.in
By Aswathy P B, MA Communication (Media Practice)
The University of Hyderabad’s ASPIRE initiative features three cutting-edge incubation centers: ASPIRE-BioNEST, ASPIRE-TBI, and ASPIRE TIDE. These centers provide state-of-the-art infrastructure and necessary instrumentation to support startups in Life Sciences, Pharma & Chemistry, Materials, and IT & Electronics.
Since its inception, ASPIRE has supported over 80 startups, helping them translate ideas into technologies and creating a vibrant entrepreneurial ecosystem on campus.
The UoH Herald decided to feature the startups and this is the first one in the series – Entrepreneurial Excellence Series.
For more details please visit https://aspire.uohyd.ac.in/